TY - JOUR AU - Lorenz, R.; Dietlein, M.; Reiners, C. TI - Nuclear medical inpatient treatment in Germany T2 - Analysis of the structured quality reports 2004 to 2008 TT - Stationäre nuklearmedizinische Therapie in Deutschland SN - 0029-5566 SN - 2567-6407 PY - 2010 JO - Nuklearmedizin JF - Nuklearmedizin - NuclearMedicine LA - DE VL - 49 IS - 02 SP - 49 EP - 57 DA - 2018/01/24 KW - Nuclear Medicine KW - inpatient treatment KW - radioiodine therapy KW - utilization review KW - utilization statistics KW - numerical data AB - All public licensed hospitals of Germany are obligated since 2004 to establish and to publish a structured biennial quality report. The aim of this study was to analyse the quality reports from 2008 of clinics with nuclear-medicine therapy ward and to investigate developments for the inpatient nuclear-medicine therapy by comparing the results with the quality reports of the years 2004 and 2006. Methods: All available structured quality reports of clinics with a nuclear-medicine therapy ward of the years 2004, 2006 and 2008 were evaluated. Results: The total number of inpatient treatment cases in 2008 amounted to 54 190 (2006: 54 884; 2004: 57 366). This corresponds to a decrease of 5.5% in comparison to 2004. The number of the therapy wards decreased at the same time to currently 117 (2006: 120; 2004: 124). Remarkable changes were found in the spectrum of the main diagnosis. Thus, the most frequent diagnosis with the ICD-code E05 (hyperthyroidism) decreased continuously from 37 747 treatments in 2004 and 34 764 in 2006 to 31 756 in the year 2008. In contrast, the ICD-diagnoses for thyroid cancer (C73, Z08) with 14 761 cases in 2008 increased with time (2006: 13 426; 2004: 12 581). Conclusions: In analogy to the observations from Europe after introduction of an iodine prophylaxis the improved iodine supply in Germany has led to a decline of the radioiodine therapy due to hyperthyroidism. PB - Schattauer GmbH DO - 10.3413/nukmed-0296 UR - http://www.thieme-connect.de/products/ejournals/abstract/10.3413/nukmed-0296 ER -